How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Immunotherapy
Resistance to Immune Checkpoint Inhibition in Pancreatic Cancer
Research presented at SITC 2019 looks at 2 different mechanisms for resistance to immune checkpoint inhibition in pancreatic ductal adenocarcinoma.
Daratumumab Increased Myeloma Patient Risk for Listeria
Patients with multiple myeloma may want to avoid consumption of foods associated with Listeria.
PI3K Inhibitors Increased T-Cell Expansion Ahead of CAR-T Cell Therapy
Concomitant use of inhibitors allowed for the manufacture of more potent T cells.
Triple-Negative Breast Cancer Now Has a Targeted Agent
Dr Hamilton discusses the approval of atezolizumab for first-line treatment of metastatic triple-negative breast cancer in combination with nab-paclitaxel chemotherapy.
Why We Need to Change How We Look for Renal Cell Carcinoma Biomarkers
Proangiogenic or proimmunogenic genomic and transcriptomic signatures in the tumor microenvironment may have predictive value.
Hyperprogression Halts Study of Nivolumab in Peripheral T-Cell Lymphomas
For patients with relapsed/refractory peripheral T-cell lymphomas, single-agent nivolumab showed limited benefit, in part because of hyperprogressive disease.
Early Look at the Feasibility and Safety of a Third-Generation Anti-CD19 CAR-T Therapy
A third-generation anti-CD19 CAR-T cell therapy showed no major safety concerns and early signs of clinical activity for patients with lymphoid malignancies.
Eosinophilic Fasciitis: A Rare Immune-Related Adverse Effect of Immune Checkpoint Inhibitor Therapy
Diagnosis and management of EF in the setting of cancer immunotherapy requires close collaboration between patient’s oncologist, dermatologist, and rheumatologist.
Immune Checkpoint Inhibitors May Be Overused at End of Life
With responses to ICIs taking 2 to 3 months, administration of these therapies to patients with poor life expectancies may not be appropriate.
Next post in General Oncology
